How Moderna Went From Pandemic Hero to Vaccine Victim
The biotech's mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to vaccine rules.
----
Paramount Nominates Three New Directors, Sets July 2 Annual Meeting
The entertainment company is in the midst of negotiations to settle a lawsuit by President Trump against its CBS News division.
----
Universal, Warner and Sony Are Negotiating AI Licensing Rights for Music
The talks with AI startups concern how the labels-and their artists-would get paid for music's use in generative AI models.
----
Walt Disney Co. to Lay Off Hundreds
Walt Disney is laying off several hundred people globally across multiple divisions, including marketing for film and television, TV publicity, casting and development, and corporate financial operations.
----
Exactech Revises Bankruptcy Exit Plan Without TPG Legal Releases
Exactech's plan would include a litigation trust, allowing injury claimants to seek damages from TPG.
----
Tesla sales plunge in France, showing Elon Musk may have a long way to go to restore the brand
Tesla's sales have been under pressure in Europe, even after the rollout of a souped-up Model Y.
----
Jamie Dimon Says He Isn't Retiring Anytime Soon
The chief executive's would-be successors will need to wait at least a few more years.
----
Campbell's Snack Business Struggles as Consumers Get Pickier About Food Spending
The maker of soups and snacks logged higher sales in its latest quarter and backed its full-year outlook, but it warned about tariffs.
----
BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb
BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech's BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker.
----
Amazon's Pricing Mechanism Could Breach Competition Law, German Regulator Says
Officials said tools that Amazon.com uses to highlight competitively priced goods and filter out overpriced listings in its online marketplace could be breaking competition rules.
----
Kymera Stock Jumps 41%. New Dermatitis Pill Could Challenge Regeneron Blockbuster.
Its dermatitis drug could win at least 10% of annual sales in dermatitis by 2030-or about $3 billion.
----
Indian Billionaire Gautam Adani Comes Under New Scrutiny from U.S. Prosecutors
The Justice Department is investigating whether Adani's companies violated U.S. sanctions on Iran, after charging him in a bribery case last year.
----
Cleveland-Cliffs Stock, Other Steel Shares Soar on Trump's Bombshell Steel Tariff Announcement
President Trump said tariffs on imported steel would go to 50% from 25%. That has investors excited early Monday.
----
Meta Aims to Fully Automate Ad Creation Using AI
Advertising powered by artificial intelligence is a core part of Chief Executive Mark Zuckerberg's vision for the company's future.
(END) Dow Jones Newswires
June 02, 2025 23:00 ET (03:00 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.